Stoke Has Cash for the Wait-But Q2 Only Tightens, Doesn't Solve, the 2028 Dravet Bet

Cash buys time, but the valuation still hinges on EMPEROR

Stoke remains a funded wait-for-proof story, not a de-risked one. The most important update from Q2 is balance-sheet comfort: the company ended June with $354.3 million and subsequently sold $65.7 million through its ATM program, bringing total liquidity to about $420 million in cash, cash equivalents, and marketable securities. That extends the runway, but it does not settle the thesis.

The core bet is still zorevunersen in Dravet syndrome. With 162 patients enrolled in the Phase 3 EMPEROR trial and a data readout anticipated in Q3 2027, the next year is really about waiting for evidence rather than waiting for funding. Stoke also has a pre-NDA meeting with FDA scheduled for H2 2026 and plans to initiate a rolling U.S. NDA submission in Q1 2027. The cash reduces financing stress; it does not remove execution or clinical risk.

Early data support the disease-modifying narrative, but they are still early

What bulls can point to

Stoke now has 4-year longitudinal data from the Phase 1/2a open-label extension showing statistically significant improvements in cognition and behavior across 1, 2, 3, and 4 years, along with continued durability in seizure reductions. Zorevunersen was also generally well tolerated, with some patients treated for more than 5 years.

Those findings matter because the value proposition in Dravet syndrome is not limited to seizure reduction. Longer-term improvements in cognition and behavior could broaden the therapeutic narrative if they hold up in a controlled setting. For now, though, they are best understood as supportive early signal rather than confirmatory evidence.

Why the regulatory path looks cleaner

Stoke is no longer just waiting for a distant proof event. It has a pre-NDA meeting with FDA scheduled for H2 2026, plans to initiate a rolling U.S. NDA submission in Q1 2027, and expects the filing to be completed as EMPEROR data become available. That makes the approval pathway easier to model, even though the pivotal evidence is still ahead.

The key point is not that the case is proven. It is that the sequence around approval is becoming clearer while the company has the cash to wait for the result.

The main risk is still that early data cannot do the regulatory job

Open-label results are not approval data

The bear case does not require a clinical disaster. It only requires investors to stop treating supportive early data as if they can replace pivotal evidence. Stoke can currently point to the Phase 1/2a open-label extension for durability and mechanism, but approval will rest on the controlled Phase 3 package from EMPEROR.

That is why the coming milestones matter so much. The pre-NDA meeting with FDA scheduled for H2 2026 may help clarify what the agency expects from the data package, and the planned initiate a rolling U.S. NDA submission in Q1 2027 will show whether Stoke can stay on schedule. Those are process milestones, not evidence.

Cash lowers dilution pressure, but it does not create operating traction

Stoke's liquidity also lowers near-term financing stress, but it does not change the fact that the company remains externally funded. The Q1 update noted $80.7 million raised through selective ATM sales in first quarter 2026, which reinforces that point.

The same caution applies to management alignment. Stoke did appoint Thomas McCauley as Chief Scientific Officer in July, but it also announced inducement grants under Nasdaq Listing Rule 5635(C)(4) in July, after similar grants in June and May. That helps retain talent, but it is not the same as insider buying or self-funded operations.

What would strengthen the case from here

• Treat the pre-NDA meeting with FDA scheduled for H2 2026 as the first real checkpoint. The signal investors need is not optimism by itself, but clearer alignment on the data package and submission timeline.
• Watch whether Stoke actually follows its plan to initiate a rolling U.S. NDA submission in Q1 2027. Execution there matters as much as the eventual readout.
• Monitor whether enrollment of 162 patients complete in Phase 3 EMPEROR translates into a smooth transition from data collection to filing and, later, commercial preparation.

For now, the cleanest way to frame Stoke is simple: the Q2 update improved the wait, but it did not end it.